Back to search results

First-in-Human Study of SON-DP for Advanced Solid Tumors

This study is testing a new treatment called SON-DP for people with advanced or metastatic (spread to other parts of the body) solid tumors that have returned, are difficult to treat, or who cannot tolerate standard treatments. SON-DP is a targeted therapy designed to change cancer cells into normal tissue cells, rather than killing them. This study will look at the safety and how well SON-DP is tolerated, as well as how it moves through the body. You may be able to join if you have a solid tumor, and for some parts of the study, specifically breast, pancreatic, ovarian, or colorectal cancer. The main goals are to identify any side effects and determine the highest safe dose of SON-DP. This study is currently recruiting up to 150 participants.

Study design
This is a Phase I, open-label study, meaning both you and the study team will know which treatment you are receiving. It is a 'first-in-human' study, meaning SON-DP is being tested in people for the first time.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 7 months after your first dose of SON-DP.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05989724

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

UNKNOWN
PHASE1Ages 18+InterventionalTreatment
Qurgen Inc.
~150 participants
Updated 2024-04-24 on ClinicalTrials.gov
What's tested:SON-DP

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.
Measured over Up to 7 months after the first dose
+1 more outcome measured

Conditions

Solid Tumor
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Colorectal Cancer

Explore related trials

Breast CarcinomaColorectal CarcinomaMalignant Ovarian NeoplasmPancreatic CarcinomaSolid Neoplasm

Where it's being run

5 sites across 5 states
Arizona1
Michigan1
North Carolina1
Oklahoma1
Texas1

Study leadership

  • Britney Winterberger · STUDY_DIRECTOR · Tigermed America LLC.

Who to contact

Jianjun Wang
[email protected]
+1（248）607 8451
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.Up to 7 months after the first dose
  • MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II)During 28-day DLT observation period